Abstract: Compositions and methods are provided including a plurality of analyte detection agents, each analyte detection agent includes a labile tag operatively coupled to the analyte detection agent, each labile tag includes a signal that is different from each other labile tag and each analyte detection agent targeting a different analyte.

Abstract: The present invention generally relates to a positioning device for positioning the limbs of a patient placed on an operating room table and to methods of using such a device. In one embodiment, the device provides for the positioning of the arms of a patient positioned supine on an operating room table.

Abstract: Methods treating an aberrant activation of ?v?3 integrin are provided. The methods include administering a therapeutically effective amount of inducible co-stimulator ligand (ICOSL) polypeptide to a subject in need thereof. Methods of identifying subjects having a kidney injury are also provided.

Abstract: Methods treating cancer are provided. The methods include intratumorally administering a therapeutically effective dose of a vaccine to a subject in need thereof.

Abstract: A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb) against mouse p402 and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and/or monoclonal antibody against p402 (mAb-p402 a3-1d) are disclosed.

Abstract: A composition and a method for the treatment of a neurodegenerative disorder is provided. The composition includes an inhibitor of RANTES and/or an inhibitor of eotaxin. The method includes administering a composition comprising an inhibitor of RANTES and/or an inhibitor of eotaxin to the subject in need thereof to treat the neurodegenerative disorder.

Abstract: Described herein is a method for treating an autoimmune disease in a patient including administering to the patient in need thereof, a pharmaceutically effective amount of an epigenetic enzyme inhibitor.

Abstract: The present invention generally relates to methods for predicting the response of HER2-directed therapies in cancer and to methods of treating the cancer based on the prediction. In one embodiment the cancer is breast cancer. In another embodiment, the method predicts the response to treatment with trastuzumab.

Abstract: Disclosed herein is a device and method for reducing or stopping the flow of blood in a patient. The patient may be treated with an intravenous line, such as a central line. The device may have a plunger including a pressure pad that applies pressure to the bleeding vein to reduce or stop the flow of blood in an engaged position of the plunger.

Abstract: An assay and a method for identifying a prebiotic to treat a subject in need thereof to promote intestinal barrier integrity or to blunt an inflammatory response are provided.

Abstract: A method and system for encouraging the selection of healthy products with a vending machine are provided. The method includes providing a vending machine that displays an inventory of products. Each product of the inventory of products includes a dispensing countdown time displayed on the vending machine. The method also includes receiving a first customer selection of a first product from the inventory of products, where the first product has a first dispensing countdown time. Additionally, the method includes actuating a countdown timer to count down to zero seconds from the first dispensing countdown time. The method also includes dispensing the first product once the countdown timer reaches zero seconds. The first product is only dispensed if a customer does not select a second product having a second dispensing countdown time before the first dispensing countdown time counts down to zero seconds.

Abstract: A vascular impedance measuring device may comprise a processing component capable of processing raw pressure and flow wave data and a pressure measuring component capable of providing pressure wave data from a specified point in a vessel and forwarding the pressure wave data to the processing component. The device may further include a flow measuring component capable of providing flow wave data from the specified point or a point near the specified point in the vessel and forwarding the flow wave data to the processing component. The processing component processes the raw pressure and flow wave data to produce an estimation of vascular impedance of the vessel from the specified point of measure and may provide data to a feedback system for therapy.

Abstract: Methods of treating neutrophilic dermatoses and PTPN6 deficiencies in a subject are provided. The methods include administering a therapeutically effective amount of a pharmaceutical composition comprising spleen tyrosine kinase (SYK) inhibitor to the subject.

Abstract: The present invention generally relates to compositions and methods for treating a neurological disorder in a subject, the method including administering to the subject in need of such treatment a composition including a therapeutically effective amount of a CCR5 antagonist. The CCR5 antagonist may be, for example, maraviroc. The neurological disorder may be, for example, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies or multiple system atrophy.

Abstract: Fusion peptides and methods of inhibiting GrB-EHITSN or a fragment thereof are provided. The fusion peptides include an NPF peptide and a cell-permeable peptide operably connected thereto. Fusion peptides and methods of inhibiting activity of GrB-EHITSN or fragment thereof are provided. An aspect includes a fusion peptide comprising an isolated NPF peptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2 and a cell-permeable peptide operably connected to the isolated NPF peptide, wherein the fusion peptide inhibits activity of GrB-EHITSN or a fragment thereof.

Abstract: The present invention generally relates to compositions and methods for stimulating astroglial uptake and degradation of amyloid-? protein aggregates. One aspect of the invention provides a method of preventing or treating Alzheimer's disease including administrating a clinically effective amount of combination of vitamin A or a derivative thereof and an agonist of proliferator-activated receptor a (“PPAR?”) to a human or veterinary subject in need of such treatment.

Abstract: This disclosure relates to pharmaceutical compositions and formulations useful for inhibiting the progression of glycine encephalopathy. The pharmaceutical compositions and formulations may include glyceryl tribenzoate. The pharmaceutical compositions and formulations may include glyceryl dibenzoate. The pharmaceutical compositions and formulations may be orally administered to the patient.

Abstract: Methods of treating a viral infection in a subject are provided. The methods include administering a therapeutically effective amount of a pharmaceutical composition comprising ginkgolic acid (GA) to the subject in need thereof, where the virus comprises an enveloped virus. Further provided are specific viral infections that can be treated using the methods.

Abstract: Methods of modulating peroxisome proliferator-activated receptor ? (PPAR?) activity in a cell in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR? ligand to the subject where the PPAR? ligand is selected from 3-hydroxy-2,2-dimethyl butyrate (HMB), hexadecananamide (HEX) and 9-octadecenamide (OCT). Methods of treating dementia, neurodegenerative disorders, lysosomal storage diseases and body weight disorders in a subject in need thereof are provided. The methods include administering an effective amount of a PPAR? ligand to the subject.

Abstract: Methods for measuring a panel of biomarkers in a subject suspected of having breast cancer are provided. The methods include obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample, the panel comprising at least 5 biomarkers selected from the group comprising LPC(18:3), LPC(20:2), LPC(20:1), LPC(20:0), PC(32:1), PC(34:4), PC(38:3), PC(40:5), PC(40:3), PC(44:11), ePC(32:2), ePC(38:3), C19:1 CE, C19:0 CE, and C20:0 CE, wherein the measurement comprises measuring a level of each of the at least 5 biomarkers.